IP Verse

Allergan Pharmaceuticals International Limited opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Allergan Pharmaceuticals International Limited

Patent Number:
EP2800811
Title:
Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of Transcription
Applicant:
CHARPENTIER, EMMANUELLE
Opposition Date:
Feb 11, 2018

Latest patents of Allergan Pharmaceuticals International Limited opposed by its competitors

Patent:
EP3509559
Grant Date:
Jul 19, 2023
Title:
Injectable Gels Comprising Cross-Linked Hyaluronic Acid And Hydroxyapatite, And Methods Of Manufacturing Thereof
Oppositions:
1
Patent:
EP3024479
Grant Date:
Feb 8, 2023
Title:
High Potency Pancreatin Pharmaceutical Compositions
Oppositions:
1
Patent:
EP3003360
Grant Date:
Oct 7, 2020
Title:
High Potency Pancreatin Pharmaceutical Compositions
Oppositions:
1
Patent:
EP2922532
Grant Date:
Mar 6, 2019
Title:
5-Aminosalicylic Acid Capsule Formulation
Oppositions:
1
Patent:
EP2818160
Grant Date:
Nov 8, 2017
Title:
Enteric Coated, Low-Strength Pancrelipase Formulations
Oppositions:
1

Competitors of Allergan Pharmaceuticals International Limited

MATHYS & SQUIRE LLP

CAMULON LIMITED

CHARPENTIER, EMMANUELLE

Want to track Allergan Pharmaceuticals International Limited?

Feel free to send us a message here and we will get back to you